Abstract
Introduction
In the Netherlands, each year 4500 women are diagnosed with gynaecological cancer, among which 1900 are endometrial cancers, 750 are cervical cancers and 60 are vaginal cancers.
1 About 35% of these women are treated with pelvic radiotherapy (RT), either as primary or post-surgical treatment.
5 Treatment for gynaecological cancer may cause physical and psychological side effects that interfere with the women's sexuality. Reported sexual problems among gynaecological cancer survivors are a tightened and shortened vagina, diminished lubrication, dyspareunia, post-coital bleeding, and loss of sexual desire, enjoyment and satisfaction. 18, 19, 21, 22, 31 Most studies agreed that the negative effect of gynaecological cancer treatment on sexual functioning was more pronounced when treatment included RT, compared to surgery alone. 13, 20, 30 The negative effect of RT is attributed to decreased lubrication, shortening and tightening of the vagina as a result of formation of fi brosis. 30, 49 Few studies investigated the effect of the regular use of vaginal dilators on the development or prevention of vaginal stenosis after treatment with RT. These studies showed that regular vaginal dilator use is associated with less vaginal shortening and/or tightening. 39, 62, 63 It is not clear how the (changes in) vaginal dimensions were assessed in these studies, nor what the cause-and-effect relationship was between dilator use and the vaginal measurements. Although more empirical evidence is needed, in clinical practice regular dilator use is found to reduce the risk of shortening and/or tightening due to adhesions and fi brosis. 65 Dilator use is therefore advocated in many guidelines and reviews. 44, 67, 148 It is important to provide consistent and uniform, evidence-based counselling regarding when and how dilators should be used. [68] [69] [70] In two survey studies from the UK and Australia there was consensus among professionals that women undergoing pelvic RT for gynaecological malignancies should receive information about vaginal dilation. 71, 149 Also, professionals recommended to insert a vaginal dilator during 5-10 minutes. 71, 149 Other recommendations were inconsistent. 71, 149 No consensus existed regarding the most appropriate time interval after RT, the frequency and duration of dilator use, dilator sizes offered, insertion techniques, or the appropriateness of dilator use among sexually inactive patients. 71, 149 Moreover, there was no consensus on the content of instructions regarding patients' sexual rehabilitation.
There is a clear need for consensus on all of these aspects in order to further investigate the effi cacy of a standardizes procedure of sexual rehabilitation and dilator use after RT. Consensus is needed specifi cally on which specifi c gynaecological cancer patients should receive information about sexual rehabilitation and dilator use, what type of health care provider should provide this information, counselling and support, what should be the practical guidelines for use of vaginal dilation.
The Delphi method proved to be an anonymous and economic tool to reach consensus on best practice issues in health care settings. [150] [151] [152] [153] [154] At fi rst a questionnaire addressing the opinion of an expert panel is assessed. Then a second questionnaire is developed that is based on the fi rst questionnaire without the statements on which consensus was reached. It is offered to the panel containing anonymous feedback on the panels' agreement. This encourages the panel to reconsider their fi rst response to the statements.
This study used the Delphi method and aimed to determine clear recommendations on the content and procedures of patient information provision and support, regarding sexual rehabilitation and vaginal dilator use after RT for gynaecological cancers. This was done conducting an online three-round Delphi study among recognized gynaecologic oncology professionals, from different cancer centres and with various areas of clinical expertise.
Materials and Methods

Participants
Eligible participants were radiation oncologists, gynaecologic oncologists and oncology nurses, with recognized clinical expertise in the treatment of gynaecological cancer patients receiving pelvic RT, and expert knowledge on vaginal dilation in this population. It was expected that 30 participants, representing all Dutch gynaecological cancer centres and each of the three specialisms equally, would create a heterogeneous and representative panel.
151-154
Clinicians who participated in the Dutch gynaecological cancer network received an invitation e-mail, together with a brochure explaining the study content and the Delphi method, and an online informed consent form. Non-responders were approached by phone one week later. Prior to enrolment, it was ascertained that participants had the intention to complete all rounds of the study and had access to the Internet. At the conclusion of the study the participants received a 20-euro gift voucher as a token of appreciation. The study was approved by the Leiden University Medical Centre Medical Ethics Committee.
Questionnaire
The questionnaire consisted of statements and questions addressing participants' opinions on seven different categories (see Table 1 , page 64). The questionnaire was developed based on literature on sexuality and vaginal dilation after pelvic RT, [68] [69] [70] [71] 149, 155 and previous in-depth interviews with professionals involved in gynaecological cancer treatment. Items were pilot tested on comprehensibility among fi ve experienced researchers in the fi eld of gynaecologic oncology and/or conducting Delphi studies. Answers were measured using 7-point Likert scales varying from 1 (totally disagree) to 7 (totally agree) (n = 53), single-(n = 8) and multiple-choice questions (n = 6).
The questionnaire also consisted of items measuring demographic and work-related characteristics (e.g. age and the years of experience in the fi eld).
The Delphi process
The present Delphi method was based on a frequently published standard design. [150] [151] [152] [153] [154] The questionnaire elicited responses in three rounds. After each round, the degree of consensus was calculated. In case no consensus was reached on an item, the group response was fed back to the participants in the next round. Participants were asked to comment on their answers in case it differed from the group response. Items on which no consensus was reached and that, according to the comments by participants, appeared to be unclear were adapted.
The degree of consensus on the six multiple-choice questions that were used in Round 1 could not be calculated. Therefore, the multiple-choice questions were not counted as part of the total number of items in Round 1 and reformulated as 25 Likert scale statements in the next round.
An online Delphi study was conducted to allow anonymous inclusion of professionals across diverse centres and expertise and avoid that a specifi c expert might dominate the consensus process. Participants were asked to fi ll in each questionnaire within 2 weeks. Non-responders were send a reminder by e-mail and, if necessary, received a subsequent phone call after 1 week.
Consensus
It was decided beforehand that consensus was reached when at least 70% of participants' answers fell within the two lowest or highest answer categories on a Likert Table 1 Description of the seven item categories used in the questionnaire.
Description of the item category
Responsibilities that radiation oncologists, gynecological oncologists and oncology nurses have regarding their patients' sexual rehabilitation (e.g. providing practical advice on how to cope with sexual problems).
Speci c patient groups that should receive information regarding sexual rehabilitation using vaginal dilators.
Type of dilator that is best advised.
The rationale that health care providers should use to advise the use of dilators.
Information and instructions that should be provided regarding the use of vaginal dilators and sexual intercourse during sexual rehabilitation.
Type of health care provider that should provide information regarding sexual rehabilitation and vaginal dilator use, the time interval at which information should be provided, and the informational resource that should be used.
Type of health care provider that should provide sexual health support during rehabilitation and dilator use, and to what extent sexual health support should be given by a radiation oncologist, gynecological oncologist or oncology nurse. scale, or within one category on a single-or multiple-choice question. In addition, to reach consensus, an interquartile range (IQR) of ≤1 was required. An IQR is a measure of statistical dispersion representing the distance between the 25 th and the 75 th percentile. A smaller IQR signifi es a large consensus and a IQR ≤1 represents good consensus on a 7-point Likert scale. 153, 154 When the degree to which consensus was reached differed between the three specialisms, this will be reported.
Item category
Responsibility
Statistical analyses
Descriptive statistics (percentages and IQR's) were calculated to measure consensus. The group response on items on which no consensus was reached, were fed back to the participants in Round 2 by stating the median, and in Round 3 by stating the median together with the modus. All statistical analyses were done using the Statistical Package for the Social Sciences (SPSS) version 20.0.
Results
Participants
Thirty-two clinicians were approached, of which 30 agreed to participate with a mean age of 48 years old (see Figure 1 , page 66, for more information on the Delphi panel characteristics). Experts from three different disciplines and all 12 gynaecological cancer centres in the Netherlands were included. Twenty-seven participants had more than 5 years of experience within the fi eld of gynaecologic oncology (90%) and 24 participants regularly or often gave patients sexological support (80%). All participants (100%) completed the three rounds.
Consensus results
The specifi c results of the consensus rounds are shown in Supplemental Information 1 and 2, which illustrate all items that reached consensus (in Round 1, 2 and 3) and all items that did not reach consensus respectively.
Consensus Round 1
Consensus was reached for 22/50 items in Round 1 (44%, see Supplemental Information 1, page 71). After Round 1 eight items were formulated differently based on comments by participants. Furthermore, one item was removed from the questionnaire because this question was not specifi c enough. The degree with which consensus was reached, was equal between the three professional groups except for one item. The gynaecologic oncologists reached the consensus that it is part of their responsibility to evaluate their patients' sexual functioning (n = 10, 100% agreed and IQR = 1.00). The radiation oncologists almost reached the same consensus (n = 8, 80% agreed and IQR = 1.25). However, the oncology nurses disagreed (IQR = 4.50) about whether this is their responsibility.
The panel did uniformly agree that it is important to give patients advice on how to cope with fear for sexual contact after treatment and, if necessary, to refer patients to a sexologist after treatment with RT for gynaecological cancers. Furthermore, participants agreed that all sexually active cervical and vaginal cancer patients with a partner, younger than 70, should always be informed about sexual rehabilitation using vaginal dilators. Regarding the use of vaginal dilators, participants thought that dilators should be prescribed with the rationale that regular dilator use prevents the formation of vaginal adhesions and stenosis, and keeps the vagina accessible for penetration in the future. Vaginal dilators should be used together with lubricants. Furthermore, it was thought that the frequency of vaginal dilator use could be reduced in case the patient has resumed sexual intercourse. Health care providers, instead of the patient herself, should initiate the provision of information and patient support on this topic during follow-up appointments after treatment. Monitoring of dilator use and discussion of barriers or problems with its use should take place during each follow-up appointment.
Consensus Round 2
The panel reached consensus on 31/52 items in Round 2 (60%, see Supplemental Information 1, page 71) with an equal degree of consensus between the three specialisms. After Round 2, 14 items were formulated differently based on comments by participants. Also, one item was removed from the questionnaire because this question was less specifi c than another item addressing the same subject. 
Consensus Round 3
Consensus was reached for 8/21 items in Round 3 (38%, see Supplemental Information 1, page 71) and the degree of consensus was equal between the three specialisms. The panel agreed that it is best if radiation oncologists give the fi rst introduction and information about vaginal dilation. More extensive information should be provided during the fi rst post treatment follow-up appointment. According to the panel, the use of vaginal dilators can also help patients to reduce fear of bodily changes and fear of sexual activity. If preferred, patients can use a vibrator as a vaginal dilator. Furthermore, health care providers should counsel patients on which type(s) of dilator they can use, but the patient ultimately decides. To prevent adhesions, inserting the vaginal dilator for 1 to 3 minutes was thought to be suffi cient. 
No consensus
No agreement was reached on whether or not to provide standard information about sexual rehabilitation using vaginal dilators to vulvar and endometrial cancer patients, patients older than 70 years, and patients who were not sexually active before treatment (see Supplemental Information 2, page 75). Some participants recommended tailoring the information for these patient groups; depending on the specifi c type(s) of treatment, age, wish to retain sexual activity, personal and medical situation. Some participants commented to inform every patient about sexuality and vaginal dilator use after treatment with regard to possible needs in the future. Furthermore, participants did not agree on whether dilation should be started between 2 and 4 weeks after RT (n = 20, 67%) or later. It was commented that it is important for the vaginal mucosa to have healed before dilation is started, which often takes 4 weeks after completion of RT. 
5 CHAPTER
Discussion
An online three-round Delphi study was conducted to assess the content and procedures of patient information provision and support regarding sexual rehabilitation and vaginal dilator use after RT for gynaecological cancer. The study was conducted among 30 gynaecologic oncology experts from 12 gynaecological cancer centres. The panel equally represented radiation oncologists, gynaecologic oncologists and specialized oncology nurses, involved and experienced in counselling, and the follow-up of gynaecological cancer patients after RT. All participants completed the three rounds. The degree to which consensus was reached, was equal between the three professional groups. Previously, no specifi c recommendations could be made regarding the content and procedures of information provision and support during sexual rehabilitation and vaginal dilator use. 67, 71, 149 This study offers a clear consensus on these topics.
Consensus was reached that information about sexual rehabilitation and vaginal dilator use should be given to all sexually active cervical and vaginal cancer patients, younger than 70. Moreover, comments by the participants made clear that vulvar and endometrial cancer patients, patients older than 70, and patients that were not sexually active before treatment, should receive care tailored to their needs. The participants also agreed that radiation oncologists should initiate and provide information about sexual side effects of RT, rehabilitation and preventive measures including vaginal dilator use prior to treatment. Additionally, in line with previous suggestions, more extensive dedicated psychological and practical support should preferably be initiated and given by specifi cally trained oncology nurses.
156
Although in this study no clear consensus was reached on the best time to start dilator use, most participants recommended to start between 2-4 weeks after completion of RT (n = 20, 67%), or as soon as the vaginal mucosa is healed (which is usually around 4 weeks). This was also the most commonly cited time interval in the studies of White & Faithfull (2006) and Lancaster (2004) . 71, 149 Furthermore, there was consensus that the frequency with which dilators should be used, preferably 2-3 times a week, could be reduced in case the patient has resumed sexual intercourse.
The panel agreed that it is important to gradually use a bigger cylinder circumference in time. Participants in this study also agreed that each dilator should be inserted during 1-3 minutes, which is in contrast to previous recommendations of 5-10 minutes 67, 71, 149 Furthermore, the panel agreed it is best to perform dilation 9-12 months, whereas in previous studies about half of the respondents recommended indefi nite use. 71, 149 However, in contrast to the aforementioned survey studies, 22,23 his present study conducted the Delphi method among a heterogeneous panel. Therefore, the results of this study were thought to refl ect the opinion of all professionals involved in counselling and the follow-up of gynaecological cancer patients after RT.
Adapting items for the next round in the Delphi study obviously poses a risk of a self-fulfi lling prophecy.
151 However, the items concerned were adapted using experts' comments in a systematic way and all the adapted items were pilot tested on comprehensibility again among fi ve experienced researchers in the fi eld. The professionals that participated in this study were expected to be potential users of the fi ndings and, consequently, were thought to form the most useful expert panel. In a separate in-depth interview study the perspective of gynaecological cancer patients on sexual rehabilitation and dilator use after pelvic RT will be investigated. The patient's perspective on this topic is required to be able to improve patient care, since it is expected that these patients have additional needs. For example, participants in this study considered the rigid plastic dilator sets the most suitable type of dilator to prescribe, whereas patients might have preferred a softer fl exible dilator. 70 The effi cacy of regular dilator use can only be assessed in a randomized controlled trial if there is a standardized procedure of sexual rehabilitation and vaginal dilator use. Using the Delphi method, a common consensus was created out of the available expertise. It is therefore important to further investigate whether the results of this study are generally applicable in clinical practice and support patients during their sexual rehabilitation after pelvic RT, before fi nal policy decisions can be made.
In conclusion, the results of this study offer clear consensus-based recommendations for the education and support of gynaecological cancer patients treated with pelvic RT, during sexual rehabilitation and vaginal dilator use. Based on these results, an intervention has been developed and is currently pilot tested in which patients receive support during sexual rehabilitation and vaginal dilator use after pelvic RT. This study was a fi rst step towards the improvement of gynaecological cancer patient support during their sexual rehabilitation after pelvic RT.
Responsibility
It is the health care providers' responsibility to give 22 73 1.00 patients advice on how to cope with fear for sexual contact after treatment.
It is desirable to refer patients to a sexologist in case 29 97 1.00 simple sexological advice does not suf ce.
According to gynecological oncologists, it is the health 10 100 1.00 care providers' responsibility to evaluate their patients' sexual functioning. * Target Patients with a partner have to be informed about vaginal 25 83 0.00 dilation.
Vaginal dilator
The circumference of a dilator is considered important 21 70 1.00 during usage.
Rationale
The rationale that health care providers use to prescribe 24 80 0.00 vaginal dilation should at least contain that dilation prevents the formation of vaginal adhesions.
The rationale that health care providers use to prescribe 25 83 0.00 vaginal dilation should at least contain that dilation keeps the vagina accessible for any form of penetration in the future.
Vaginal dilation should start preventively, before the 27 90 1.00 formation of vaginal adhesions.
Content
The frequency with which vaginal dilators are used can 28 93 0.00 instructions be lowered in case the patient also has successful sexual intercourse. 
Rationale
It is useful to add to the rationale that using dilators can help 29 96 0.00 patients to reduce fear for bodily changes and sexual activity. It is suf cient to use Vaseline tampons 9 to 12 months 24 80 0.00 after treatment.
Whether or not the partner is actively involved during the 27 90 0.00 use of dilators should depend on patients' needs.
Information
The panel agreed that radiation oncologists could best 27 90 0.00 provision introduce vaginal dilation.
More extensive information should be given during the 24 80 0.00 rst follow-up appointment after treatment.
a Number of participants that agreed on the item (N); b Percentage of participants that agreed on the item (%); c Interquartile range of the total group response (IQR); * This statement did not appear applicable to all participants' and was removed from the questionnaire after Round 1. Radiation oncologists almost agreed (n = 8 agreed and IQR = 1.25) and oncology nurses disagreed (IQR = 4.50) about whether it is part of their responsibility to evaluate their patients' sexual functioning; † This item was inversely formulated in the original questionnaire. 
